文献速递白血病

NG2抗原是MLL重排B细胞急性淋巴细胞白血病的治疗靶点

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2019-01-11

MLL重排B-ALL预后差且易复发,需新治疗靶点。研究利用患者来源异种移植模型发现NG2对MLL重排B-ALL静脉移植后植入至关重要;用软骨素酶ABC或抗NG2单克隆抗体阻断NG2可动员白血病细胞从骨髓至外周血,与长春新碱、糖皮质激素和左旋天冬酰胺酶联用提高完全缓解率、无事件生存并延迟复发。

要点

  • NG2对MLL重排B-ALL经静脉移植后的植入至关重要。
  • 软骨素酶ABC或抗NG2单抗阻断NG2可动员骨髓白血病细胞至外周血。
  • NG2拮抗剂与VxL方案联用提高完全缓解率和无事件生存。

核心结论

  • NG2可作为MLL重排B-ALL的治疗靶点,阻断NG2与VxL化疗联用可提高疗效。

研究设计与样本

  • 研究采用患者来源异种移植(PDX)模型,在体内外评估NG2阻断对MLL重排B-ALL的作用。

主要发现

  • 静脉移植后,NG2对MLL重排B-ALL的植入至关重要。
  • 使用软骨素酶ABC或抗NG2特异性单克隆抗体在体内阻断NG2,经流式细胞术和3D共聚焦成像分析证实,可显著动员MLL重排B-ALL原始细胞从骨髓至外周血。
  • 与任一NG2拮抗剂联用时,VxL治疗获得更高的完全缓解率,并因此提高无事件生存率、延迟复发时间。
  • 机制上,抗NG2单克隆抗体不诱导抗体依赖性细胞介导的细胞毒作用,也不诱导补体依赖性细胞毒作用;NG2阻断通过将MLL重排B-ALL原始细胞动员至外周血,克服骨髓基质介导的化学保护,使其更易受化疗攻击。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. MLLr leukemias are characterized by the specific expression of chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2). NG2 was recently shown involved in leukemia invasiveness and central nervous system infiltration in MLLr-B-ALL, and correlated with lower event-free survival (EFS). We here hypothesized that blocking NG2 may synergize with established induction therapy for B-ALL based on vincristine, glucocorticoids, and L-asparaginase (VxL). Using robust patient-derived xenograft (PDX) models, we found that NG2 is crucial for MLLr-B-ALL engraftment upon intravenous (i.v.) transplantation. In vivo blockade of NG2 using either chondroitinase-ABC or an anti-NG2-specific monoclonal antibody (MoAb) resulted in a significant mobilization of MLLr-B-ALL blasts from bone marrow (BM) to peripheral blood (PB) as demonstrated by cytometric and 3D confocal imaging analysis. When combined with either NG2 antagonist, VxL treatment achieved higher rates of complete remission, and consequently higher EFS and delayed time to relapse. Mechanistically, anti-NG2 MoAb induces neither antibody-dependent cell-mediated not complement-dependent cytotoxicity. NG2 blockade rather overrides BM stroma-mediated chemoprotection through PB mobilization of MLLr-B-ALL blasts, thus becoming more accessible to chemotherapy. We provide a proof of concept for NG2 as a therapeutic target for MLLr-B-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lopez-Millan B, Sanchéz-Martínez D, Roca-Ho H, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia. 2019. PMID: 30635633. doi:10.1038/s41375-018-0353-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。